Stock futures are slipping with traders wary that the momentum seen in the prior session could falter in the face of fresh geopolitical headwinds. Investors opened the day on edge, as fears of renewed U.S.-China trade friction resurfaced and overshadowed what had been a tentative rebound in risk appetite.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gold continues to dominate the headlines as the precious metal surged to a new record high above $4,179 per ounce, before pulling back. Silver has followed suit, rallying in tandem on the wintry winds of uncertainty.
In the energy sector, WTI prices are down on the weak broader markets as well as bearish warnings from the IEA.
In pre-market trading, S&P 500 futures fell 1.09%, Nasdaq futures fell 1.37% and Dow futures fell 0.96%.
Check out this morning’s top movers from around Wall Street, compiled by The Fly.
HIGHER –
- Astria Therapeutics (ATXS) up 40% after entering into a definitive agreement under which BioCryst (BCRX) has agreed to acquire the company for a mix of cash and stock representing an implied value of $13.00 per Astria share
UP AFTER EARNINGS –
DOWN AFTER EARNINGS –
- Goldman Sachs (GS) down 3%
- JPMorgan (JPM) down 1%
- Johnson & Johnson (JNJ) down 1%
- BlackRock (BLK) down 1%
LOWER –
- BioCryst (BCRX) down 8% after entering into a definitive agreement under which the company has agreed to acquire Astria for a mix of cash and stock representing an implied value of $13.00 per Astria share
- General Motors (GM) down 2% after announcing charges of $1.6B in GM North America in the three months ended September 30, based on a planned strategic realignment of electric vehicle capacity and manufacturing footprint to consumer demand
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics Announces Merger with BioCryst
- BioCryst to acquire Astria Therapeutics for $13.00 per share
- Promising Developments in Astria Therapeutics’ Clinical Program Justify Buy Rating
- Astria Therapeutics initiates ORBIT-EXPANSE trial
- Astria Therapeutics begins enrollment in EU for ALPHA-ORBIT trial